ClinicalTrials.gg
Active, not recruitingNCT05615623Updated Apr 21, 2026

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG

A Phase 1/2 interventional study of Exablate and Doxorubicin in Brain Tumor, sponsored by InSightec. Active, not recruiting at 1 site in Canada. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by InSightec · Phase 1/2, Interventional, and Device feasibility

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
5 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 180 studies in Brain Neoplasms with a site in Canada — 23 open to participants now, 45 under way, 10 of them phase 3. Brain Neoplasms · Canada.

Planned enrollment
145th of 161
10 · median 70
Started
2023
with 3 others
Phase 1/2
9 of 180
none open now
Primary completion
2026-06
later than 14 of 44 live
Registered
166th of 180
by date
Lead sponsor
5 of 180
InSightec

Among the 180 studies in Brain Neoplasms with a site in Canada, this one is the 145th largest by planned enrollment of the 161 interventional ones that give a count, is one of 4 that started in 2023, is one of 9 in phase 1/2, reaches primary completion later than 14 of the 44 other live ones, and was the 166th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

23 of the 180 studies in Brain Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 5 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Brain Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients

Read the detailed description

This is a prospective, single arm, non-randomized feasibility study to evaluate the safety, feasibility and preliminary efficacy of Blood Brain Barrier Disruption (BBBD) using the Exablate Type 2 system in pediatric patients with Diffuse Intrinsic Pontine Gliomas (DIPG) undergoing Doxorubicin chemotherapy. The study will be conducted at a single center in Canada. Patients will undergo 3 treatment cycles, approximately 4 -6 weeks apart. The study aims to establish feasibility and safety of Exablate BBBD in conjunction with Doxorubicin in the treatment of pediatric DIPG and assess preliminary efficacy in this patient population.

03

Conditions studied

  • Brain Tumor

Browse trials for

Keywords

  • DIPG
  • Focused Utrasound
  • Chemotherapy
  • Phase I trial
  • Pediatrics
04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 5 and 18 years, inclusive
  • Patient diagnosed with DIPG
  • At least 4-week and not greater than 12 weeks from completion of radiation therapy
  • Post-radiation imaging does not show evidence of necrosis/ hemorrhage or other features that contraindicate MRgFUS
  • Able to attend all study visits and with of at least 6 months
  • Able and willing to give consent and/or assent or have a legal guardian who is able and willing to do so
  • If on , stable or decreasing dose for at least 7 days prior to study entry
  • If brain surgery occurred, at least 14 days passed since last brain surgery and the patient is fully recovered and neurologically stable

Exclusion criteria

Exclusion Criteria:

  • Evidence of cranial or systemic infection
  • Known life-threatening systemic disease
  • Previous treatment with complete cumulative doses of Doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones
  • to Doxorubicin. - Known sensitivity to DEFINITY® ultrasound contrast agent or known to perflutren microsphere or its components, e.g., polyethylene glycol. - Known sensitivity to gadolinium-based contrast agents
  • Active seizure disorder or epilepsy (seizures despite medical treatment) for a minimum of 4 weeks prior to first cycle/Exablate BBBD procedure captured by history
  • Patients with positive status. - ( to prevent/treat brain edema are permitted)
  • Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular malformation, cerebral aneurysm, or vasculitis
  • Hypertension per age
  • History of a bleeding disorder, coagulopathy or with a history of spontaneous tumour hemorrhage
  • Anti-coagulant therapy, or medications known to increase risk of hemorrhage, (e.g., ASA, non-steroidal anti-inflammatory drugs [NSAIDs], statins) within prior to treatment
  • Patient receiving bevacizumab (Avastin) therapy or increasing doses of steroids
  • Symptoms and signs of increased intracranial pressure
  • Previous participation in other chemotherapy, molecularly targeted therapy or immunotherapy treatment-related phase 1 or 2 trials
  • Tumor not visible on any pre-therapy or post-radiation imaging
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Blood Brain Barrier Disruption (BBBD)

    Exablate MR Guided Focused Ultrasound for Blood Brain Barrier Disruption with Doxorubicin for treating pediatric patients with DIPG

    Device: Exablate · Drug: Doxorubicin

Interventions

  • DeviceExablate

    Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors

    Also known as: Exablate BBBD

  • Doxorubicin infusion

    Also known as: Adriamycin, Rubex

06

What researchers measure

Primary outcomes

  1. Adverse Events

    All adverse events from first treatment to end of study will be documented and reported according to the CTCAE terminology and severity scale

    Time frame: 2 years

Secondary outcomes

  1. Blood Brain Barrier Disruption (BBBD)

    BBBD will be assessed as a comparative ratio measured in pre and post-sonication contrast-enhanced MR images

    Time frame: Immediately post BBBD sonication

Other outcomes

  1. Tumor Volume

    Average volume of contrast-enhancement on post sonicated MRI scans will be compared with pre-sonicated scans

    Time frame: Immediately post BBBD sonication

  2. Progression Free Survival (PFS) and Overall Survival (OS)

    PFS will be assessed based on the Response Assessment in Pediatric Neuro-Oncology (RAPNO) scale. Tumor related biomarkers will be compared before and after the BBBD procedure

    Time frame: 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jun 2026, 41 months after the start.

Of 72 phase 1/2 interventional studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 105. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2022
First posted
Nov 14, 2022
StartActual
Jan 4, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Oct 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05615623
Lead sponsor
InSightec
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Jan 4, 2023
Primary completion
Jun 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Apr 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxorubicin

Start the discussion